Fulcrum Therapeutics Inc FULC

NAS: FULC | ISIN: US3596161097 17/05/2024

7,550 USD (-3,14%)

(-3,14%) 17/05/2024

Toon enkel gratis nieuws

20 juni 2023 · FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

31 mei 2023 · FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

18 maart 2021 · Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference · Persbericht

4 maart 2021 · Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results · Persbericht

26 februari 2021 · Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET · Persbericht

26 februari 2021 · Fulcrum Therapeutics Recognizes Rare Disease Day 2021 · Persbericht

22 januari 2021 · Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares · Persbericht

20 januari 2021 · Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock · Persbericht

19 januari 2021 · Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock · Persbericht

19 januari 2021 · Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe